The Laotian Bear version of Sotorasib, as the first generic version of the world's first approved KRAS G12C inhibitor original drug, is produced by Laotian Bear Pharmaceutical Co., Ltd., providing a more accessible treatment option for patients with advanced non-small cell lung cancer carrying this mutation.
Is there a Laotian generic version of Sotorasib?
Yes, there is a Laotian generic version of Sotorasib. The Laotian Bear version of Sotorasib is available in a specification of 120mg*56 tablets per box. For more information, it is recommended that you contact professional customer service for detailed consultation.
Practical guidance for the correct use of Sotorasib
To help patients use Sotorasib safely and effectively, the following information is crucial. First, Sotorasib is available only with a prescription. Do not give the medication to others (even if they have the same symptoms), nor use it for indications not approved by a doctor. Store the medication at room temperature between 20°C and 25°C. The bottle has a child-resistant cap; keep the medication out of the reach of children and pets. Regarding the composition, the active ingredient in Sotorasib is Sotorasib, and the inactive ingredients include microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate; the film coating consists of polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide. Before use, patients should inform their doctor of all medical conditions, especially liver problems, lung or breathing problems not related to lung cancer, and whether they are pregnant or breastfeeding. At the same time, provide your doctor with a complete list of medications, including prescription drugs, over-the-counter drugs, vitamins, dietary supplements, and herbal products, to avoid drug interactions. If a dose is missed by more than 6 hours, do not make up the missed dose. Instead, continue with the next dose as scheduled the following day. Do not take double doses. All potential drug interactions should be reported to your doctor, especially those with antacids. If any signs of liver problems (such as jaundice, tea-colored urine, upper right abdominal pain) or lung problems (new or worsening shortness of breath, cough, fever) occur, contact your doctor immediately. Your doctor may adjust the dose, temporarily stop treatment, or permanently discontinue treatment based on adverse reactions. Following these guidelines will help maximize the efficacy of Sotorasib and minimize potential risks.
Detailed explanation of drug interactions and mechanism of action of Sotorasib
Special attention should be paid to drug interactions when Sotorasib is combined with other medications. First, avoid co-administration with proton pump inhibitors (e.g., omeprazole) and H2 receptor antagonists (e.g., famotidine), as these potent antacids can significantly reduce the blood concentration of Sotorasib. If it is unavoidable to use antacids (such as locally acting antacids like aluminum magnesium carbonate, aluminum hydroxide), Sotorasib should be taken 4 hours before or 10 hours after the antacid. Second, avoid concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin), as they may accelerate Sotorasib metabolism and reduce its efficacy. In addition, Sotorasib may affect the blood concentration of CYP3A4 substrates (e.g., certain sedative-hypnotics, immunosuppressants); even small concentration changes may lead to therapeutic failure of these substrates. If concomitant use is unavoidable, adjust the dose of the substrate based on its prescribing information. Meanwhile, co-administration of Sotorasib with P-glycoprotein (P-gp) substrates (e.g., digoxin) may increase substrate toxicity, and a reduction in the dose of the P-gp substrate is recommended. From a pharmacological perspective, Sotorasib irreversibly binds to the unique cysteine of the KRAS G12C protein via a covalent bond, locking the protein in an inactive state, thereby blocking downstream signaling without affecting wild-type KRAS. In vitro and in vivo models have shown that this drug inhibits cell growth and promotes apoptosis only in tumor cells carrying the KRAS G12C mutation, demonstrating high targeting specificity.
